Status:
COMPLETED
A Study of LY3502970 in Healthy Overweight and Obese Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Obese
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is ...
Eligibility Criteria
Inclusion
- Participants with stable body weight for at least one month prior to randomization.
- Participants with body mass index (BMI) of greater than or equal to (≥) 27.0 kilograms per meter squared (kg/m²)
- Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential
Exclusion
- Have known allergies to LY3502970 or other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs
- Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders
- Have any type of diabetes with hemoglobin A1c (HbA1c) ≥6.5 %
Key Trial Info
Start Date :
May 26 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 9 2022
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT05313802
Start Date
May 26 2022
End Date
September 9 2022
Last Update
October 18 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Qps-Mra, Llc
Miami, Florida, United States, 33143
2
ICON Early Phase Services Lenexa Center
Lenexa, Kansas, United States, 66219
3
ICON Early Phase Services
San Antonio, Texas, United States, 78209